Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) shares rose 2.4% during trading on Tuesday . The stock traded as high as $67.50 and last traded at $66.59, with a volume of 255,668 shares traded. The stock had previously closed at $65.02.

RARE has been the subject of several research analyst reports. JPMorgan Chase & Co. set a $110.00 price target on Ultragenyx Pharmaceutical and gave the stock a “buy” rating in a research report on Monday, August 8th. Credit Suisse Group AG restated a “buy” rating and set a $101.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, May 25th. Canaccord Genuity restated a “buy” rating and set a $120.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Friday, July 15th. Jefferies Group restated a “buy” rating and set a $109.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, May 10th. Finally, Leerink Swann restated a “buy” rating and set a $86.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Thursday, August 25th. Three research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $97.32.

The stock’s market cap is $2.60 billion. The company has a 50 day moving average price of $61.74 and a 200-day moving average price of $62.27.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($1.46) EPS for the quarter, missing analysts’ consensus estimates of ($1.44) by $0.02. During the same period last year, the business posted ($0.83) earnings per share. On average, equities analysts forecast that Ultragenyx Pharmaceutical Inc. will post ($5.93) EPS for the current fiscal year.

In other news, insider Sunil Agarwal sold 649 shares of the company’s stock in a transaction on Thursday, July 21st. The stock was sold at an average price of $52.68, for a total transaction of $34,189.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Emil D. Kakkis sold 20,000 shares of the company’s stock in a transaction on Friday, July 15th. The stock was sold at an average price of $50.85, for a total value of $1,017,000.00. Following the sale, the chief executive officer now owns 513,597 shares of the company’s stock, valued at $26,116,407.45. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Ultragenyx Pharmaceutical stock. Ameriprise Financial Inc. boosted its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 24.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 470,334 shares of the biopharmaceutical company’s stock after buying an additional 93,380 shares during the period. Ameriprise Financial Inc. owned approximately 1.21% of Ultragenyx Pharmaceutical worth $52,762,000 as of its most recent filing with the SEC.

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.